FDA Approves Talazoparib for gBRCAm HER2-negative Locally Advanced or Metastatic Breast Cancer

FDA also approved the BRACAnalysis CDx test to identify patients who are eligible for talazoparib
26 Oct 2018
Breast cancer;  Personalised medicine;  Anticancer agents & Biologic therapy

On 16 October 2018, the US Food and Drug Administration (FDA) approved talazoparib (TALZENNA, Pfizer Inc.), a poly (ADP-ribose) polymerase (PARP) inhibitor, for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2‑negative locally advanced or metastatic breast cancer. Patients must be selected for therapy based on an FDA-approved companion diagnostic for talazoparib. 

Approval was based on EMBRACA (NCT01945775), an open‑label trial randomising 431 patients (2:1) with gBRCAm HER2‑negative locally advanced or metastatic breast cancer to receive talazoparib (1 mg) or physician’s choice of chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine). All patients were required to have a known deleterious or suspected deleterious gBRCA mutation and must have received no more than 3 prior cytotoxic chemotherapy regimens for locally advanced or metastatic disease. Patients were required to have received treatment with an anthracycline and/or a taxane (unless contraindicated) in the neoadjuvant, adjuvant, and/or metastatic treatment setting. 

The primary efficacy outcome was progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, as assessed by blinded independent central review. Estimated median PFS was 8.6 and 5.6 months in the talazoparib and chemotherapy arms, respectively (HR 0.54; 95% CI: 0.41, 0.71; p < 0.0001). 

The prescribing information includes warnings and precautions for myelodysplastic syndrome/acute myeloid leukaemia, myelosuppression, and embryo-foetal toxicity. Most common (≥20%) adverse reactions of any grade were fatigue, anaemia, nausea, neutropenia, headache, thrombocytopenia, vomiting, alopecia, diarrhoea, decreased appetite. 

FDA also approved the BRACAnalysis CDx test (Myriad Genetic Laboratories, Inc.) to identify patients with breast cancer with deleterious or suspected deleterious gBRCAm who are eligible for talazoparib. The effectiveness of the BRACAnalysis CDx test was based on the EMBRACA trial population for whom deleterious or suspected deleterious gBRCAm status was confirmed with either prospective or retrospective testing with BRACAnalysis CDx. 

The recommended talazoparib dose is 1 mg taken as a single oral daily dose, with or without food. 

Full prescribing information for TALZENNA is available here

FDA granted this application priority review. 

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

Last update: 26 Oct 2018

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings